These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 208782)

  • 1. Production of migration inhibitory factor (MIF) by human leukocytes following exposure to Epstein-Barr virus.
    Wilson GL; Young BG
    Cell Immunol; 1978 Jun; 38(1):147-56. PubMed ID: 208782
    [No Abstract]   [Full Text] [Related]  

  • 2. Cell-mediated immunity to Epstein-Barr virus and a blocking factor in patients with infectious mononucleosis.
    Lai PK; Mackay-Scollay EM; Fimmel PJ; Alpers MP; Keast D
    Nature; 1974 Dec; 252(5484):608-10. PubMed ID: 4372559
    [No Abstract]   [Full Text] [Related]  

  • 3. [Immunology of Epstein-Barr virus in lymphoproliferative diseases].
    Bachmann AE; Giraudo Conesa LC; Braun M
    Medicina (B Aires); 1974 Mar; 34(2):157-66. PubMed ID: 4368156
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of different Epstein-Barr virus-determined antigens (EBNA, EA, and VCA) on the leukocyte migration of healthy donors and patients with infectious mononucleosis and certain immunodeficiencies.
    Szigeti R; Masucci MG; Henle W; Henle G; Purtilo D; Klein G
    Clin Immunol Immunopathol; 1982 Jan; 22(1):128-38. PubMed ID: 6288294
    [No Abstract]   [Full Text] [Related]  

  • 5. Lymphocyte responses to EBV-associated antigens in infectious mononucleosis, and Hodgkin's and non-Hodgkin's lymphoma patients, with the leukocyte adherence inhibition assay.
    Chan SH; Wallen WC; Levine PH; Periman P; Perlin E
    Int J Cancer; 1977 Mar; 19(3):356-63. PubMed ID: 191408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epstein-Barr virus-related serology in Hodgkin's disease.
    Henle W; Henle G
    Natl Cancer Inst Monogr; 1973 May; 36():79-84. PubMed ID: 4355353
    [No Abstract]   [Full Text] [Related]  

  • 7. The Epstein-Barr virus (EBV) in human pathology. Results of a serological investigation of a hospital population.
    Dalens M; Didier J; Pris J; Enjalbert L
    Biomedicine; 1973 Jul; 18(4):336-45. PubMed ID: 4139980
    [No Abstract]   [Full Text] [Related]  

  • 8. Cell mediated immunity during infectious mononucleosis to Epstein-Barr virus associated antigens.
    Periman P; Levine PH; Ablashi DV; Royston I
    Int J Cancer; 1977 Oct; 20(4):506-11. PubMed ID: 199544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epstein-barr-virus nuclear antigen.
    Vonka V; Hirsch I
    Prog Med Virol; 1982; 28():145-79. PubMed ID: 6283600
    [No Abstract]   [Full Text] [Related]  

  • 10. Cytotoxic antibodies to cultured lymphoblasts unrelated to Epstein-Barr virus.
    Yang CS; Hewetson JF
    Int J Cancer; 1974 Oct; 14(4):530-8. PubMed ID: 4376526
    [No Abstract]   [Full Text] [Related]  

  • 11. [Epstein-Barr virus. Its participation in lymphoproliferative and anaplastic processes].
    Fejes M; Bachmann AE; Mochanko K
    Medicina (B Aires); 1978; 38(6 Pt 1):700-16. PubMed ID: 220495
    [No Abstract]   [Full Text] [Related]  

  • 12. Antibodies to a new antigen induced by Epstein-Barr virus in patients with nasopharyngeal carcinoma, leukemia, malignant lymphoma, and in control groups.
    Ida S; Sairenji T; Hinuma Y
    Gan; 1972 Feb; 63(1):49-55. PubMed ID: 4339712
    [No Abstract]   [Full Text] [Related]  

  • 13. Abrogation of cell-mediated immunity by a serum blocking factor isolated from patients with infectious mononucleosis.
    Wainwright WH; Veltri RW; Sprinkle PM
    J Infect Dis; 1979 Jul; 140(1):22-32. PubMed ID: 88489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specific neutralizing antibodies in Epstein-Barr virus associated diseases.
    Rocchi G; Hewetson J; Henle W
    Int J Cancer; 1973 May; 11(3):637-47. PubMed ID: 4364719
    [No Abstract]   [Full Text] [Related]  

  • 15. [Diagnostic significance of determining antibodies to antigens of the Epstein-Barr virus in infectious mononucleosis].
    Urazova LN; Podoplekin VD; Odintsova LN; Lepekhin AV
    Lab Delo; 1989; (5):73-4. PubMed ID: 2473271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute Epstein-Barr virus infection and diffuse large-cell lymphoma.
    Sato T
    J Infect; 1985 May; 10(3):265-7. PubMed ID: 2993424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Invited discussion: relationship of titers of Epstein-Barr virus to cell-mediated immunity in patients with Hodgkin's disease.
    Levine PH; Reisher JI
    Natl Cancer Inst Monogr; 1973 May; 36():85-7. PubMed ID: 4355354
    [No Abstract]   [Full Text] [Related]  

  • 18. [Leukocyte migration inhibition elicited by Epstein-Barr virus antigen. Reaction potential in infectious mononucleosis as well as in states of immune deficiency and immunosuppression].
    Szigeti R; Klein E; Masucci MG; Ernberg I; Masucci G; Svedmyr E; Klein G
    Orv Hetil; 1982 May; 123(20):1217-21. PubMed ID: 6287380
    [No Abstract]   [Full Text] [Related]  

  • 19. Correlation between mixed lymphocyte cultures and anti-Epstein Barr virus (EBV) antibodies in Hodgkin's disease and non Hodgkin lymphoma patients.
    Sasiain MC; Fejes M; Ares BR; Brezavscek D; Bachmann AE
    Biomedicine; 1981 Oct; 35(5):153-6. PubMed ID: 6274439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of cell-mediated immunity to Epstein-Barr herpesvirus in infectious mononucleosis as shown by leukocyte migration inhibition.
    Lai PK; Alpers MP; MacKay-Scollay EM
    Infect Immun; 1977 Jul; 17(1):28-35. PubMed ID: 195902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.